Cargando…

Early Outpatient Treatment With Remdesivir in Patients at High Risk for Severe COVID-19: A Prospective Cohort Study

BACKGROUND: Early treatment of coronavirus disease 2019 (COVID-19) with remdesivir in high-risk patients, including those with immunosuppression of different causes, has not been evaluated. The objective of this study was to assess the clinical effectiveness of early remdesivir treatment among patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rajme-López, Sandra, Martinez-Guerra, Bernardo A, Zalapa-Soto, Jessica, Román-Montes, Carla M, Tamez-Torres, Karla M, González-Lara, María F, Hernandez-Gilosul, Thierry, Kershenobich-Stalnikowitz, David, Sifuentes-Osornio, José, Ponce-de-León, Alfredo, Ruíz-Palacios, Guillermo M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585545/ https://www.ncbi.nlm.nih.gov/pubmed/36285176 http://dx.doi.org/10.1093/ofid/ofac502

Ejemplares similares

Large-scale screening for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) among healthcare workers: Prevalence and risk factors for asymptomatic and pauci-symptomatic carriers, with emphasis on the use of personal protective equipment (PPE)
por: Rajme-López, Sandra, et al.
Publicado: (2021)

Outcomes of patients with severe and critical COVID-19 treated with dexamethasone: a prospective cohort study
por: Martinez-Guerra, Bernardo A., et al.
Publicado: (2021)

Post-COVID-19 syndrome and quality of life impairment in severe COVID-19 Mexican patients
por: Román-Montes, Carla Marina, et al.
Publicado: (2023)

283. Post COVID-19 syndrome and quality of life impairment in a cohort of severe COVID-19
por: Roman-Montes, Carla M, et al.
Publicado: (2022)

Fungal Infections in the ICU during the COVID-19 Pandemic in Mexico
por: Roman-Montes, Carla M., et al.
Publicado: (2023)

In-hospital mortality from severe COVID-19 in a tertiary care center in Mexico City; causes of death, risk factors and the impact of hospital saturation
por: Olivas-Martínez, Antonio, et al.
Publicado: (2021)

Correction: In-hospital mortality from severe COVID-19 in a tertiary care center in Mexico City; causes of death, risk factors and the impact of hospital saturation
por: Olivas-Martínez, Antonio, et al.
Publicado: (2022)

Risk factors associated with prolonged hospital length-of-stay: 18-year retrospective study of hospitalizations in a tertiary healthcare center in Mexico
por: Marfil-Garza, Braulio A., et al.
Publicado: (2018)

Adverse Effects Associated With the Use of Antimalarials During The COVID-19 Pandemic in a Tertiary Care Center in Mexico City
por: Lozano-Cruz, Oscar Arturo, et al.
Publicado: (2021)

Antimicrobial Resistance Patterns and Antibiotic Use during Hospital Conversion in the COVID-19 Pandemic
por: Martinez-Guerra, Bernardo A., et al.
Publicado: (2021)

Risk Factors Associated with the Development of Hospital-Acquired Infections in Hospitalized Patients with Severe COVID-19
por: Solís-Huerta, Fernando, et al.
Publicado: (2023)

Remdesivir Use in Patients Requiring Mechanical Ventilation due to COVID-19
por: Lapadula, Giuseppe, et al.
Publicado: (2020)

Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa
por: Jo, Youngji, et al.
Publicado: (2021)

Remdesivir and Mortality in Patients With Coronavirus Disease 2019
por: Diaz, George A, et al.
Publicado: (2021)

Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality
por: Olender, Susan A, et al.
Publicado: (2021)

Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center Experience
por: Kalligeros, Markos, et al.
Publicado: (2020)

Predictors of Mortality in Patients with Infections Due to Carbapenem-Resistant Gram-Negative Bacteria
por: Rivera-Villegas, Hector Orlando, et al.
Publicado: (2023)

Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)
por: Jittamala, Podjanee, et al.
Publicado: (2023)

POSC41 Cost-Effectiveness Analysis of Remdesivir for the Treatment of COVID-19 Hospitalized Adults in Mexico
por: Ponce-de-León, A, et al.
Publicado: (2022)

Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID)
por: Absalón-Aguilar, Abdiel, et al.
Publicado: (2021)

Experience of Treating COVID-19 With Remdesivir and Convalescent Plasma in a Resource-Limited Setting: A Prospective, Observational Study
por: Koirala, Janak, et al.
Publicado: (2021)

Importance of differentiating Mycobaterium bovis in tuberculous meningitis
por: González-Duarte, Alejandra, et al.
Publicado: (2011)

Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)
por: Hedskog, Charlotte, et al.
Publicado: (2023)

Safety of Outpatient Parenteral Antimicrobial Therapy in Nonagenarians
por: Shrestha, Nabin K, et al.
Publicado: (2020)

Remdesivir for Outpatient Management: Time to Wait, Not to Act
por: Mohapatra, Prasanta Raghab
Publicado: (2022)

Outpatient Antibiotic Prescribing Practices for Uncomplicated Urinary Tract Infection in Women in the United States, 2002–2011
por: Kobayashi, Miwako, et al.
Publicado: (2016)

Symptoms of COVID-19 Outpatients in the United States
por: Pullen, Matthew F, et al.
Publicado: (2020)

Mycobacterium tuberculosis complex bacteremia among HIV and non-HIV patients in a Mexican tertiary care center
por: Tamez-Torres, Karla Maria, et al.
Publicado: (2018)

Outpatient Therapies for COVID-19: How Do We Choose?
por: Lee, Todd C, et al.
Publicado: (2022)

Epidemiology of Invasive Fungal Infections in Latin America
por: Sifuentes-Osornio, Jose, et al.
Publicado: (2012)

Remdesivir Is Associated With Reduced Mortality in COVID-19 Patients Requiring Supplemental Oxygen Including Invasive Mechanical Ventilation Across SARS-CoV-2 Variants
por: Mozaffari, Essy, et al.
Publicado: (2023)

Outpatient Antibiotic Prescribing in Massachusetts, 2011–2015
por: Klevens, R Monina, et al.
Publicado: (2019)

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
por: Gottlieb, Robert L., et al.
Publicado: (2021)

Value and Clinical Impact of an Infectious Disease-Supervised Outpatient Parenteral Antibiotic Therapy Program
por: Petrak, Russell M., et al.
Publicado: (2016)

Use of Ceftriaxone and Benzylpenicillin in Outpatient Parenteral Antimicrobial Therapy: Spectrum vs Cost
por: Kalatharan, L, et al.
Publicado: (2023)

Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort
por: Mozaffari, Essy, et al.
Publicado: (2021)

Outpatient Parenteral Antibiotic Treatment vs Hospitalization for Infective Endocarditis: Validation of the OPAT-GAMES Criteria
por: Pericàs, Juan M, et al.
Publicado: (2022)

Protocol-Driven Intensive Outpatient Management of Pregnant Patients With Symptomatic Coronavirus Disease 2019
por: Soffer, M D, et al.
Publicado: (2020)

Blood Inflammatory Biomarkers Differentiate Inpatient and Outpatient Coronavirus Disease 2019 From Influenza
por: Luciani, Lauren L, et al.
Publicado: (2023)

Impact of Pseudomonas aeruginosa Isolation on Mortality and Outcomes in an Outpatient Chronic Obstructive Pulmonary Disease Cohort
por: Jacobs, David M, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tvm7hbtt8cj6bii8hr5rrvkcu2